Efficacy and Safety of Minocycline in Acute Spontaneous Intracerebral Hemorrhage
ConditionIntracerebral Hemorrhage
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorBeijing Tiantan Hospital
About this trial
This is a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. It aims to evaluate the efficacy and safety of oral minocycline in patients with acute spontaneous intracerebral hemorrhage within 48 hours of onset.
Eligibility criteria
Qualifiers
CT-confirmed spontaneous supratentorial intracerebral hemorrhage;
Aged 18 to 80 years;
Within 48 hours of symptom onset;
Hematoma volume 15-40 ml;
Disqualifiers
Secondary intracerebral hemorrhage (traumatic, tumor-related, vascular malformation, aneurysm, coagulation disorder, etc.);
Intraventricular hemorrhage filling one entire lateral ventricle, third ventricle, or fourth ventricle, or more than half of two lateral ventricles;
Significant subarachnoid hemorrhage (Fisher grade ≥ 3) or subdural hemorrhage;
Patients with uncontrollable hypertension ( systolic blood pressure persistently ≥ 180 mmHg despite intensive antihypertensive treatment);
Trial design
Treatments tested in this trial
- Minocycline hydrochloride capsules
- Placebo capsules of Minocycline hydrochloride capsules
Treatment groups
1,192 Participants
are divided into 2 treatment groupsLocations
41Beijing Tiantan Hospital BeijingBeijing Municipality, China
Chongqing Tongnan District People's Hospital ChongqingChongqing Municipality, China
The Second People's Hospital of Guangdong Province GuangzhouGuangdong, China
Baoding Fourth Central Hospital (Tangxian, Hebei) BaodingHebei, China
Sponsors and collaborators
Beijing Tiantan Hospital
Lead sponsor
Source ClinicalTrials.gov